IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): AGM/EGM SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items 04.02.2025 /
Administration of the maternal respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo) didn’t come with an increased risk of preterm birth or other negative neonatal